Triple Threat: OnRamp Bioinformatics, Cloudian, ScaleMatrix Combine Services for Genomic Data Analysis and...
OnRamp Bioinformatics, Cloudian, ScaleMatrix Combine Services for Genomic Data Analysis and Storage Offering
Five-Year Super Successes in Genomics and Precision Medicine
Multidimensional, computationally rich approaches represent the next wave of innovation, taking personalized medicine to the next level, while demanding more of practitioners, who in...
Glioblastoma Sex Differences Uncovered
It is widely appreciated that sex differences play a role in both the incidence of and treatment outcomes of many diseases, including some cancers....
Invitae Expands Genetic Testing with Exome Sequencing and Interpretation Services
Invitae Boosted Exome applies NGS to analyze the exons of up to 20,000 genes, using bioinformatics solutions and interpretation.
Treading with Caution: PGx Test Developers Pursue Dialogue as FDA Maintains Enforcement Stance
Developers of pharmacogenetic tests cheered in August when United Healthcare (UHC) concluded in a policy statement effective October 1, that “the use of pharmacogenetic...
Microfluidic Single-Cell DNA Analysis
Leverages droplet microfluidics to provide high-throughput single-cell DNA with a novel two-step protease workflow.
![Study published in the journal of the American Academy of Ophthalmology shows that a CRISPR-based treatment can restore retinal function in mice. [Source: Shutterstock]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1677-218x150.jpeg "Genome Editing Shows Promise for Treating Eye Disease")
Genome Editing Shows Promise for Treating Eye Disease
Researchers use CRISPR gene editing technique to restore retinal function in mice afflicted with degenerative disease retinitis pigmentosa
Clinical Mass Spec Attains Critical Mass
Clinical applications for mass spectrometry technology have exploded in recent years. Mass spectrometry analysis is often faster, cheaper, and more sensitive than other methods...
![Assurex Health has selected Agena Bioscience's MassARRAY® System for laboratory set-up and sample processing of its GeneSight Psychotropic test. [Agena Bioscience]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1136-218x150.jpeg "Assurex Health Selects Agena’s MassARRAY System Platform")
Assurex Health Selects Agena’s MassARRAY System Platform
Mass spec-based nonfluorescent detection platform chosen for lab setup and sample processing of Assurex's GeneSight Psychotropic test.
Bruker to Expand in Infectious Disease MDx with Majority Stake in Hain
Acquisition is part of Bruker's ongoing transformation of its product portfolio to achieve faster growth, dubbed Project Accelerate
